Citations

Clear

3942 citation(s) found for "To, Van".

Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
Doulamis, Ilias P. , Makri, Elpiniki, Kalamaras, Ilias , Papastergiopoulos, Christoforos , Emfietzoglou, Maria , Drosou, Anastasis , Eynde, Jef Van den , Alnsasra, Hilmi , Duque, Ernesto Ruiz , Drosou, Anastasis , Duque, Ernesto Ruiz , Briasoulis, Alexandros , Van den Eynde, Jef , Kampaktsis, Polydoros Ν. , Asleh, Rabea , Briasoulis, Αlexandros

Mayo Clinic

Journal of the American Heart Association | August 24, 2022 | Volume: 11 | Issue: 17 | Pages: No page available

10.1161/jaha.122.025507 | PMID 36000418 Get It

Background The clinical characteristics of mTOR (mammalian target of rapamycin) inhibitors use in heart transplant recipients and their outcomes have not been well described. Methods and Results We compared patients who received mTOR inhibitors within the first 2 years after heart transplantation to patients who did not by inquiring the United Network for Organ Sharing (UNOS) database between 2010 and 2018. The primary end point was all‐cause mortality with retransplantation as a competing event. Rejection, malignancy, hospitalization for infection, and renal transplantation were secondary end points. There were 1619 (9%) and 15 686 (81%) mTOR inhibitors+ and mTOR inhibitors− patients, respectively. Body mass index, induction, cardiac allograft vasculopathy, calculated panel reactive antibody, and fewer days in 1A status were independently associated with mTOR inhibitors+ status. Over a follow‐up of 10.4 years, there was no difference in all‐cause mortality after adjusting for donor and recipient characteristics (adjusted subdistribution hazard ratio, 1.03 [0.90–1.19]; P =0.66). mTOR inhibitors+ were independently associated with increased risk for rejection (odds ratio [OR], 1.43 [1.11–1.83]; P =0.005) and basal skin cancer (OR, 1.35 [1.19–1.51]; P =0.012) but not for infection or renal transplantation. Conclusions mTOR inhibitors are used in <10% patients in the first 2 years after heart transplantation and are noninferior to contemporary immunosuppression regimens in terms of all‐cause mortality, infection, malignancy, or renal transplantation. They are associated with risk for rejection.
Common Variants Near ZIC1 and ZIC4 in Autopsy‐Confirmed Multiple System Atrophy
Hopfner, Franziska , Tietz, Anja, Ruf, Viktoria , Ross, Owen A. , Koga, Shunsuke , Attems, Johannes , Beach, Thomas, Beller, Allison , Duyckaerts, Charles, Evsyukov, Valentin, Flanagan, Margaret E. , Frosch, Matthew P. , Gearing, Marla , Gelpí, Ellen , Gerpen, Jay A. van, Glass, Jonathan D. , Grinberg, Lea T. , Halliday, Glenda M. , Höllerhage, Matthias , Huitinga, Inge , Keene, Dirk, Kovács, Gábor G. , Lee, Edward B. , Xiong, Chengjie , Martı́, Marı́a José , Mackenzie, Ian R. , Mollenhauer, Brit , Neumann, Manuela , Newell, Kathy L. , Pendziwiat, Manuela , Molina‐Porcel, Laura , Rábano, Alberto , Rajput, Alex, Rajput, Ali H. , Reimann, Regina , Selvackadunco, Sashika , Simuni, Tanya , Svenningsson, Per , Trenkwalder, Claudia , Troakes, Claire , Trojanowski, John Q. , Uitti, Ryan J. , Xie, Tao , Ximelis, Teresa , Yebenes, Justo, Müller, Ulrich , Schellenberg, Gerard D., Herms, Jochen , Kuhlenbäumer, Gregor , Deuschl, Günther , Gelpi, Ellen , Van Gerpen, Jay A, Halliday, Glenda , Irwin, David J , Mollenhauer, Brit , Pantelyat, Alex , Svenningsson, Per , Höglinger, Günter U , Koga, Shunsuke , Ross, Owen A , Kovacs, Gabor G , Xiong, Chengjie , Grinberg, Lea , Molina-Porcel, Laura , Troakes, Claire , Hopfner, Franziska , Lee, Edward B , Simuni, Tanya , Dickson, Dennis W. , Aguzzi, Adriano , Cheshire, William P. , Deerlin, Vivianna M. Van , Desplats, Paula , Deuschl, Günther , Duyckaerts, Charles , Ellinghaus, David , Franke, André , Ghetti, Bernardino , Helbig, Ingo , Irwin, David J. , McKeith, Ian G. , McLean, Catriona , Pantelyat, Alexander , Peters, Annette , Matěj, Radoslav , Scott, William K. , Seeley, William W. , Stadelmann, Christine , Thomas, Alan , White, Charles L. , Wszołek, Zbigniew K. , Schellenberg, Gerard D., Höglinger, Günter U. , Flanagan, Margaret E

Mayo Clinic

Movement Disorders | August 23, 2022 | Volume: 37 | Issue: 10 | Pages: 2110-2121

10.1002/mds.29164 | PMID 35997131 Get It

ABSTRACT Background Multiple System Atrophy is a rare neurodegenerative disease with alpha‐synuclein aggregation in glial cytoplasmic inclusions and either predominant olivopontocerebellar atrophy or striatonigral degeneration, leading to dysautonomia, parkinsonism, and cerebellar ataxia. One prior genome‐wide association study in mainly clinically diagnosed patients with Multiple System Atrophy failed to identify genetic variants predisposing for the disease. Objective Since the clinical diagnosis of Multiple System Atrophy yields a high rate of misdiagnosis when compared to the neuropathological gold standard, we studied only autopsy‐confirmed cases. Methods We studied common genetic variations in Multiple System Atrophy cases (N = 731) and controls (N = 2898). Results The most strongly disease‐associated markers were rs16859966 on chromosome 3, rs7013955 on chromosome 8, and rs116607983 on chromosome 4 with P ‐values below 5 × 10 −6 , all of which were supported by at least one additional genotyped and several imputed single nucleotide polymorphisms. The genes closest to the chromosome 3 locus are ZIC1 and ZIC4 encoding the zinc finger proteins of cerebellum 1 and 4 (ZIC1 and ZIC4). Interpretation Since mutations of ZIC1 and ZIC4 and paraneoplastic autoantibodies directed against ZIC4 are associated with severe cerebellar dysfunction, we conducted immunohistochemical analyses in brain tissue of the frontal cortex and the cerebellum from 24 Multiple System Atrophy patients. Strong immunohistochemical expression of ZIC4 was detected in a subset of neurons of the dentate nucleus in all healthy controls and in patients with striatonigral degeneration, whereas ZIC4‐immunoreactive neurons were significantly reduced inpatients with olivopontocerebellar atrophy. These findings point to a potential ZIC4‐mediated vulnerability of neurons in Multiple System Atrophy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache
Schoenen, Jean , Snoer, Agneta, Brandt, Roemer B. , Fronczek, Rolf , Wei, Diana Y. , Chung, Chin‐Sang , Diener, Hans‐Christoph , Goadsby, Peter J. , Matharu, Manjit , McGinley, James S., Tepper, Stewart J. , Brandt, Roemer W, Tassorelli, Cristina , Leroux, Élizabeth , Christensen, Marie Deen, Goadsby, Peter J , Matharu, Manjit Singh , May, Arne , Diener, Hans-Christoph , Schoenen, Jean , Dodick, David W. , Fontaine, Denys , May, Arne , Jensen, Rigmor , Ferrari, Michel D. , Terwindt, Gisela M. , Ashina, Messoud , Lipton, Richard B. , Pozo‐Rosich, Patricia , Wang, Shuu‐Jiun , Martini, Daniela, Hoek, Thomas C. van den

Mayo Clinic

Cephalalgia | August 18, 2022 | Volume: 42 | Issue: 14 | Pages: 1450-1466

10.1177/03331024221120266 | PMID 36268950 Get It

In 1995, a committee of the International Headache Society developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Cluster Headache. These have not been revised. With the emergence of new medications, neuromodulation devices and trial designs, an updated version of the International Headache Society Guidelines for Controlled Clinical Trials in Cluster Headache is warranted. Given the scarcity of evidence-based data for cluster headache therapies, the update is largely consensus-based, but takes into account lessons learned from recent trials and demands by patients. It is intended to apply to both drug and neuromodulation treatments, with specific proposals for the latter when needed. The primary objective is to propose a template for designing high quality, state-of-the-art, controlled clinical trials of acute and preventive treatments in episodic and chronic cluster headache. The recommendations should not be regarded as dogma and alternative solutions to particular methodological problems should be explored in the future and scientifically validated.
Developing a Social Media Ontology Across Otolaryngology and its Subspecialties
Flagg, Candace A. , Marinelli, John P. , Carlson, Matthew L. , Kezirian, Eric J. , Dion, Gregory R. , Abel, Kathryn M. Van , Bowe, Sarah N. , Van Abel, Kathryn M , Choby, Garret , Bowe, Sarah N , Kezirian, Eric J , Dion, Greg , Choby, Garret , Hamilton, Grant

Mayo Clinic

The Laryngoscope | August 17, 2022 | Volume: 133 | Issue: 7 | Pages: 1595-1599

10.1002/lary.30345 | PMID 37294045 Get It

ObjectiveTo determine how social media is used in the dissemination of new information within otolaryngology, and to emphasize the importance of standardizing Twitter hashtag use.MethodsBased on the 2019 SCImago journal rankings, the Twitter posts from the accounts of the top three journals covering each otolaryngology subspecialty were reviewed from August 1, 2020 to May 1, 2021. Twitter posts from the primary otolaryngology‐related academic societies were also reviewed during this timeframe. A list of hashtags was generated based on a combination of the most common otolaryngologic procedures and most commonly used hashtags in the social media space. This list was then crowd‐sourced with 10 fellowship‐trained otolaryngologists for each subspecialty.ResultsHashtag use among key stakeholders in the otolaryngology social media space varies considerably. For instance, #HNSCC, #HeadAndNeckSquamousCellCarcinoma, #HeadAndNeckCancer, #HeadAndNeckCancers, #OropharyngealCancer, #OropharynxCancer, #OralCancer, and #OPSCC were all commonly used hashtags to identify posts discussing oropharyngeal squamous cell carcinoma. #HeadAndNeckCancer and #HNSCC were most popular and used in a total of 85 and 65 tweets, respectively. #HeadAndNeckCancer was found alone in 32 out of 85 tweets (38%), whereas #HNSCC was found alone in 27 out of 65 tweets (42%). A standardized hashtag ontology covering all subspecialties within otolaryngology is proposed herein.ConclusionsAdoption of a standardized social media ontology within otolaryngology will improve information dissemination across all key stakeholders. Laryngoscope, 133:1595–1599, 2023
Retrosigmoid Approach Using Suboccipital Osteoplastic Craniotomy for Resection of Vestibular Schwannoma: 2-Dimensional Operative Video
Spear, Joshua A. , Bauman, Megan M. J. , Graffeo, Christopher S. , Nassiri, Ashley M. , Carlson, Matthew L. , Gompel, Jamie J. Van , Van Gompel, Jamie J , Bauman, Megan

Mayo Clinic

Operative Neurosurgery | August 16, 2022 | Volume: 23 | Issue: 3 | Pages: e171-e172

10.1227/ons.0000000000000300 | PMID 35972099 Get It

Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder
Ommeren, Bailey Van, Athreya, Arjun P. , Bobo, William V. , Van Ommeren, Bailey

Mayo Clinic

Expert Review of Clinical Pharmacology | August 13, 2022 | Volume: 15 | Issue: 8 | Pages: 927-944

10.1080/17512433.2022.2112949 | PMID 35968639 Get It

Heterozygous NOTCH1 Variants Cause CNS Immune Activation and Microangiopathy
Helman, Guy , Zarekiani, Parand , Tromp, Samantha A. M., Andrews, Ashley , Bonkowsky, Joshua L. , Chassevent, Anna , Giorgio, Elisa , Pippucci, Tommaso , Wei, Shen, Smith‐Hicks, Constance , Vaula, Giovanna , Schimmel, Mareike , Vollert, Kurt, Shimizu, Fumitaka , Kanda, Takashi , Lynch, Matthew , Roscioli, Tony , Taft, Ryan J. , Simons, Cas , Bugiani, Marianna , Shen, Wei , Bonkowsky, Joshua L , Willemsen, Michèl A A P , Shimizu, Fumitaka , van der Knaap, Marjo S , Shen, Wei , Giorgio, Elisa , Simons, Cas , Botto, Lorenzo D. , Kuijpers, Taco Willem , Knaap, Marjo S. van der

Mayo Clinic

Annals of Neurology | August 10, 2022 | Volume: 92 | Issue: 5 | Pages: 895-901

10.1002/ana.26477 | PMID 35947102 Get It

NOTCH1 belongs to the NOTCH family of proteins that regulate cell fate and inflammatory responses. Somatic and germline NOTCH1 variants have been implicated in cancer, Adams‐Oliver syndrome, and cardiovascular defects. We describe 7 unrelated patients grouped by the presence of leukoencephalopathy with calcifications and heterozygous de novo gain‐of‐function variants in NOTCH1. Immunologic profiling showed upregulated CSF IP‐10, a cytokine secreted downstream of NOTCH1 signaling. Autopsy revealed extensive leukoencephalopathy and microangiopathy with vascular calcifications. This evidence implicates that heterozygous gain‐of‐function variants in NOTCH1 lead to a chronic central nervous system (CNS) inflammatory response resulting in a calcifying microangiopathy with leukoencephalopathy. ANN NEUROL 2022;92:895–901
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Bewicke‐Copley, Findlay , Korfi, Koorosh , Araf, Shamzah, Hodkinson, Brendan P. , Kumar, Emil , Cummin, Thomas , Ashton‐Key, Margaret , Barrans, Sharon, Hoppe, Suzan van, Burton, Cathy , Elshiekh, Mohamed , Rule, Simon , Crosbie, Nicola, Clear, Andrew , Calaminici, Maria , Runge, Hendrik F.P. , Hills, Robert K. , Sha, Chulin , Painter, Daniel , Smith, Alexandra , Naresh, Kikkeri N. , Westhead, David R. , Steele, Andrew J. , Hodson, Daniel J. , Balasubramanian, Sriram , Runge, Hendrik , Scott, David W , Nagano, Ai , Davies, Andrew , Painter, Daniel , Smith, Alexandra , Gribben, John G. , Westhead, David R , Okosun, Jessica , Steele, Andrew , Hodson, Daniel J , Johnson, Peter , Wang, Jun , Fitzgibbon, Jude , Naresh, Kikkeri N , Scott, David W. , Rimsza, Lisa M. , Menon, Geetha, Davies, John R., Davies, Andrew , Johnson, Peter , Fitzgibbon, Jude

Mayo Clinic

Blood Advances | August 10, 2022 | Volume: 7 | Issue: 5 | Pages: 845-855

10.1182/bloodadvances.2022007536 | PMID 35947123 Get It

Abstract Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic signature. In our study, we have focused attention on the changes in GEP accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo patients with DLBCL. COO remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from activated B-cell–like (ABC) to germinal center B-cell–like (GCB). Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC–DLBCLs derived from relapse-associated genes that defined clinically distinct high- and low-risk subgroups in ABC–DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of &lt;60-year–old patients with superior PFS and OS treated with ibrutinib–R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.
Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study
Hardman, John , Holsinger, F. Christopher , Brady, Grainne , Beharry, Avinash , Bonifer, Alec , D’Andréa, Grégoire , Dabas, Surender, Almeida, John R. de , Duvvuri, Umamaheswar , Floros, Peter , Ghanem, Tamer , Hamilton, David W. , Larsen, Mikkel Hjordt Holm , Magnuson, J. Scott , Miles, Brett A., Moore, Eric J. , Pantvaidya, Gouri , Rubek, Niclas , Simon, Christian , Abel, Kathryn M. Van , Poorten, Vincent Vander , Walgama, Evan , Greenlay, Emily, Potts, Laura, Balaji, Arun, Starmer, Heather M. , Stephen, S. , Roe, Justin , Harrington, Kevin J. , Paleri, Vinidh , Hardman, John C , Holsinger, F Chris , Brady, Grainne C , Bonifer, Alec T , de Almeida, John R , Ghanem, Tamer A , Gorphe, Philippe , Gross, Neil D , Hamilton, David , Kurukulasuriya, Chareeni , Larsen, Mikkel Hjordt Holm , Lin, Daniel J , Magnuson, J Scott , Meulemans, Jeroen , Miles, Brett A , Moore, Eric J , Pantvaidya, Gouri , Roof, Scott , Rubek, Niclas , Subash, Anand , Topf, Michael C , Van Abel, Kathryn M , Vander Poorten, Vincent , Walgama, Evan S , Greenlay, Emily , Potts, Laura , Balaji, Arun , Roe, Justin , Harrington, Kevin , Paleri, Vinidh , Topf, Michael C.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 9, 2022 | Volume: 114 | Issue: 10 | Pages: 1400-1409

10.1093/jnci/djac130 | PMID 35944904 Get It

Abstract Background Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness. Methods A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted (registered at clinicaltrials.gov [NCT04673929] as the RECUT study). Overall survival (OS), disease-free survival, disease-specific survivals (DSS), and local control (LC) were calculated using Kaplan-Meier estimates, with subgroups compared using log-rank tests and Cox proportional hazards modeling for multivariable analysis. Maximally selected rank statistics determined the cut point for closest surgical resection margin based on LC. Results Data for 278 eligible patients were analyzed, with median follow-up of 38.5 months. Two-year and 5-year outcomes were 69.0% and 62.2% for LC, 71.8% and 49.8% for OS, 47.2% and 35.7% for disease-free survival, and 78.7% and 59.1% for disease-specific survivals. The most discriminating margin cut point was 1.0 mm; the 2-year LC was 80.9% above and 54.2% below or equal to 1.0 mm. Increasing age, current smoking, primary tumor classification, and narrow surgical margins (≤1.0 mm) were statistically significantly associated with lower OS. Hemorrhage with return to theater was seen in 8.1% (n = 22 of 272), and 30-day mortality was 1.8% (n = 5 of 272). At 1 year, 10.8% (n = 21 of 195) used tracheostomies, 33.8% (n = 66 of 195) used gastrostomies, and 66.3% (n = 53 of 80) had maintained or improved normalcy of diet scores. Conclusions Data from international centers show TORS to treat head and neck cancers in previously irradiated fields yields favorable outcomes for LC and survival. Where feasible, TORS should be considered the preferred surgical treatment in the salvage setting.
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19
Lemaı̂tre, F. , Budde, Klemens , Bergan, Stein , Lawson, Roland , Noceti, Ofelia , Venkataramanan, Raman , Hesselink, Dennis A. , Johnson‐Davis, Kamisha L. , Winter, Brenda C. M. de , Pattanaik, Smita , Brunet, Mercè , Langman, Loralie J., Budde, Klemens , Lemaitre, Florian, Gelder, Teun van , Elens, Laure , Moes, Dirk Jan A. R. , Pawiński, Tomasz , Masuda, Satohiro

Mayo Clinic

Therapeutic Drug Monitoring | August 9, 2022 | Volume: 45 | Issue: 2 | Pages: 191-199

10.1097/ftd.0000000000001014 | PMID 35944126 Get It

Abstract: Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for the treatment of mild-to-moderate COVID-19. This combination of nirmatrelvir and ritonavir can mediate significant and complex drug–drug interactions (DDIs), primarily due to the ritonavir component. Indeed, ritonavir inhibits the metabolism of nirmatrelvir through cytochrome P450 3A (CYP3A) leading to higher plasma concentrations and a longer half-life of nirmatrelvir. Coadministration of nirmatrelvir/ritonavir with immunosuppressive drugs (ISDs) is particularly challenging given the major involvement of CYP3A in the metabolism of most of these drugs and their narrow therapeutic ranges. Exposure of ISDs will be drastically increased through the potent ritonavir-mediated inhibition of CYP3A, resulting in an increased risk of adverse drug reactions. Although a decrease in the dosage of ISDs can prevent toxicity, an inappropriate dosage regimen may also result in insufficient exposure and a risk of rejection. Here, we provide some general recommendations for therapeutic drug monitoring of ISDs and dosing recommendations when coadministered with nirmatrelvir/ritonavir. Particularly, tacrolimus should be discontinued, or patients should be given a microdose on day 1, whereas cyclosporine dosage should be reduced to 20% of the initial dosage during the antiviral treatment. Dosages of mammalian target of rapamycin inhibitors (m-TORis) should also be adjusted while dosages of mycophenolic acid and corticosteroids are expected to be less impacted.